Chronoscale Holdings Corp quarterly report, Q3 FY2023

Business context and reporting period

The supplied filing is Ekso Bionics Holdings, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2023, not a filing under the metadata name Chronoscale Holdings Corp. Ekso designs and sells medical and industrial exoskeletons. Its EksoHealth business includes the EksoNR and products acquired with the Human Motion and Control (HMC) business in December 2022; EksoWorks focuses on industrial devices.

Financial performance and position

Amounts below are in millions of dollars, except per-share data and percentages. Cash flow figures cover the nine months ended September 30.

MetricQ3 2023Q3 2022Nine months 2023Nine months 2022
Revenue$4.607$3.329$13.432$9.361
Gross profit / margin$2.456 / 53%$1.686 / 51%$6.710 / 50%$4.536 / 48%
Operating expenses$5.387$5.340$18.373$15.656
Operating loss$(2.931)$(3.654)$(11.663)$(11.120)
Net loss$(3.365)$(4.304)$(11.984)$(11.902)
Loss per share, basic and diluted$(0.24)$(0.33)$(0.88)$(0.92)
  • Cash and liquidity: Cash and restricted cash were $9.937 million at September 30, 2023, down from $20.525 million at year-end 2022. Of the September balance, $2.0 million was restricted under the bank loan covenant, leaving approximately $7.937 million unrestricted. Working capital was $14.6 million, versus $21.8 million at December 31, 2022.
  • Cash flow: Operating activities used $10.470 million over nine months, compared with $11.044 million in the prior-year period. Investing activities used $0.114 million. Cash declined by $10.588 million during the period.
  • Debt and obligations: Notes payable, net, totaled approximately $6.316 million, including the Parker acquisition note and Pacific Western Bank (PWB) term loan. The PWB loan’s maturity was extended to August 2026; it bears variable interest, and the company reported covenant compliance. The Parker note is non-interest-bearing as stated, with quarterly principal installments beginning December 31, 2023. Contractual obligations totaled $11.544 million, including purchase obligations, leases and debt payments.
  • Other balance-sheet measures: Total assets were $31.183 million, total liabilities $15.926 million and stockholders’ equity $15.257 million. Accumulated deficit was $235.931 million.

Material changes versus the prior comparable period

  • Q3 revenue rose 38% year over year, primarily on higher EksoNR and Indego device sales; the company reported selling 41 EksoHealth units. Q3 gross margin improved to 53% from 51%, which management attributed mainly to lower EksoHealth device and service costs.
  • Nine-month revenue increased 43%, with EksoHealth growth of $4.7 million partly offset by a $0.7 million EksoWorks decline. Management cited lower EVO sales, manufacturing transition delays and the absence of prior-year royalty revenue in EksoWorks.
  • Nine-month gross margin increased to 50% from 48%, primarily due to lower device costs. Operating expenses rose 17%, including increased sales, R&D and HMC-related costs. Nine-month operating loss widened, while net loss was approximately flat, partly reflecting smaller foreign-exchange losses and smaller warrant revaluation gains than in 2022.
  • Cash fell by $10.588 million over the first nine months. Shares outstanding increased to 14.235 million from 13.203 million at December 31, 2022.

Outlook, risks and unusual items

  • Going concern: Management stated that substantial doubt exists about the company’s ability to continue as a going concern for at least 12 months after issuance of the financial statements. It expects operating losses and negative operating cash flows to continue and says existing cash is insufficient for the next 12 months. Planned financing may include equity or equity-linked offerings, ATM sales, debt or receivables factoring; success and terms are not assured. If funding is inadequate, management may delay or abandon development projects, reduce costs or refocus sales efforts.
  • Market and operating risks: Management cited hospitals’ financial and staffing pressures, inflation, supply-chain constraints, lengthy purchasing cycles, competition, regulatory and reimbursement uncertainty, and foreign-currency exposure. The company does not hedge currency exposure. Customer concentration is notable: three customers represented at least 10% of Q3 revenue each.
  • Nasdaq listing: The company disclosed it was not in compliance with Nasdaq’s minimum bid-price requirement and had until March 27, 2024 to regain compliance; failure could result in delisting and impair access to capital.
  • Unusual items: In September, Parker paid $0.7 million under a warranty claim lump-sum agreement; Ekso recorded the amount as deferred revenue to be recognized as services are performed. The HMC acquisition’s preliminary valuation included $5.240 million of intangible assets and $0.431 million of goodwill. Management reported no material adverse effect expected from ordinary-course legal matters.
  • The filing provides no specific revenue, earnings or cash-flow guidance. Management’s commentary describes continued product commercialization and development, but emphasizes the need for additional financing.

Important facts for investors to verify

  • Whether Ekso can obtain sufficient financing on acceptable terms before liquidity becomes constrained, and the resulting dilution or debt burden.
  • Cash burn, restricted cash and covenant requirements, including the timing and amounts of Parker note repayments.
  • Progress in regaining Nasdaq minimum bid-price compliance by the disclosed deadline.
  • Whether EksoHealth growth can continue and whether EVO manufacturing delays and EksoWorks revenue weakness improve.
  • Customer concentration, deferred-revenue recognition and the final valuation of HMC-acquired assets and liabilities.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.